NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Klarna Group plc (NYSE: KLAR). Shareholders who purchased shares of KLAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/klarna-group-plc-loss-submission-form/?id=183590&from=3 CLASS PERIOD: This lawsuit ...

Core Viewpoint - Kyndryl Holdings, Inc. is under investigation for potential violations of federal securities laws, particularly concerning its cash management practices and financial reporting controls [1][3]. Company Overview - Kyndryl is a leading provider of enterprise technology services, offering advisory, implementation, and managed services in over 60 countries, making it the largest IT infrastructure services provider globally [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Kyndryl misrepresented its cash management practices and the drivers of its adjusted free cash flow metric, as well as the effectiveness of its internal controls over financial reporting for FY2025 and the first three quarters of FY2026 [3]. Stock Performance - Kyndryl's stock experienced a significant decline of over 52% on February 9, 2026, following the announcement of a delay in the release of its fiscal Q3 2026 financial statement due to an accounting review related to its cash management practices and SEC document requests [4][5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against KDDI Corporation for possible violations of federal securities laws and unlawful business practices, encouraging affected investors to reach out for legal options [1][2]. Investigation Details - The investigation focuses on KDDI's postponement of its earnings report disclosure, which was attributed to uncertainties regarding quarterly results linked to an internal investigation [6]. - Following the announcement of the postponement, KDDI American Depositary Receipts (KDDIY) experienced a significant decline of 11.4% on February 6, 2026 [6]. Next Steps - Affected investors who purchased or acquired KDDI shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a law firm with a national presence, representing both individual and institutional investors in various types of litigation, including securities and consumer protection cases [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of BellRing Brands, Inc. regarding a class action lawsuit related to alleged misleading statements about the company's sales growth and competitive position [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 19, 2024, to August 4, 2025 [3]. - Allegations include that the defendants claimed sales growth was due to increased consumer demand and various positive factors, while downplaying competition's impact on demand [3]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the specified period are encouraged to register for the class action by March 23, 2026, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - CVRx Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and other unlawful business practices following the announcement of weaker than expected preliminary first quarter results on April 7, 2025 [1] Company Summary - CVRx Inc. announced preliminary first quarter results that were weaker than expected, which has raised concerns among investors [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited due to allegations of securities law violations, encouraging affected investors to come forward before the April 6, 2026 deadline for lead plaintiff applications [2][4]. Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives made false and misleading statements, failing to disclose involvement in a fraudulent stock promotion scheme and the use of offshore accounts for share dumping [4]. - Specific allegations include the omission of information regarding false rumors and artificial trading activity that inflated the stock price, leading to materially misleading public statements about the company's business and prospects [4]. Group 2: Stock Performance - Pomdoctor's stock experienced a significant decline, dropping from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a decline of roughly 24% in a single trading session [5]. - This decline was attributed to heightened volatility and selling pressure amid investor concerns regarding the company's financial performance and valuation [5]. Group 3: Legal Proceedings - The firm is reminding investors of the April 6, 2026 deadline to seek the role of lead plaintiff in the federal securities class action against Pomdoctor [2]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [6]. Group 4: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, and encourages anyone with information regarding Pomdoctor's conduct to contact them [3][7].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Hub Group, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Hub Group has engaged in unlawful business practices that may have led to financial losses for investors [1][2]. - Hub Group disclosed an error on January 5, 2026, regarding the understatement of purchased transportation costs and accounts payable for the first nine months of 2025, indicating that prior financial statements should no longer be relied upon [6]. Stock Price Impact - Following the announcement of the error, Hub Group's stock price experienced a significant decline, falling as much as 27% during intraday trading on February 6, 2026, which has adversely affected investors [6]. Next Steps - Investors who purchased or acquired Hub Group shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and potential claims [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Ralliant Corporation for possible violations of federal securities laws and unlawful business practices following a significant financial impairment announcement [1][2]. Investigation Details - Ralliant reported a fourth quarter and full year 2025 non-cash goodwill impairment charge of $1.4 billion in the Test & Measurement segment, primarily due to revised expectations for the EA Elektro-Automatik business [2]. - Following this announcement, Ralliant's stock price fell by $17.89 per share, a decline of approximately 31.8%, from $56.28 to $38.39 on February 4, 2026 [2]. Next Steps - Investors who purchased Ralliant shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3].

Core Viewpoint - REGENXBIO Inc. is under investigation for potential violations of federal securities laws following the FDA's clinical holds on its RGX-111 and RGX-121 programs, which resulted in a significant decline in the company's share price by 30-35% after the announcement [1]. Regulatory Compliance - SEC disclosure rules mandate that public companies must provide material information for informed investment decisions, with Item 8.01 of Form 8-K allowing disclosure of material events not covered by other items [2]. - Rule 10b-5 under the Securities Exchange Act of 1934 prohibits material misstatements and omissions in securities transactions, covering both false statements and omissions of necessary facts [2]. Company Communication - During the Q3 2025 earnings call, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections with no observations, which may have created an asymmetric view of the company's regulatory status by not disclosing safety concerns being evaluated [3]. - The Q3 2025 earnings call transcript notably lacked any discussion regarding the RGX-111 program for MPS I, despite it being a significant pipeline asset that later faced the same FDA clinical hold, raising concerns about the completeness of information provided to shareholders [4].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its IPO on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. Financial Performance - Wealthfront reported net deposit outflows of $208 million for its first quarterly results as a public company, a significant decline from the $874 million in inflows during the same period the previous year [4]. - CEO David Fortunato attributed the outflows to falling interest rates and highlighted the strategic importance of the company's new home-lending business [4]. - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from $12.59 to $10.47 [4].